Compare · DXCM vs DYNT
DXCM vs DYNT
Side-by-side comparison of DexCom Inc. (DXCM) and Dynatronics Corporation (DYNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and DYNT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.31B, about 1982.6x DYNT ($14.3M).
- DXCM has hit the wire 6 times in the past 4 weeks while DYNT has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for DYNT).
- Company
- DexCom Inc.
- Dynatronics Corporation
- Price
- $73.36+2.55%
- $0.24+12.55%
- Market cap
- $28.31B
- $14.3M
- 1M return
- +6.92%
- -
- 1Y return
- -18.05%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Dynatronics Corporation
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. It offers orthopedic soft bracing products, which include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. The company also provides power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, recumbent bikes, and other related equipment. In addition, it offers therapeutic modality devices, such as electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. Further, the company provides clinical supplies, including exercise bands and tubing, topical analgesics, lotions and gels, orthopedic bracing, paper products, athletic tapes, and other related supplies. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, and athletic trainers, sports medicine practitioners, hospitals, clinics, and consumers, as well as online. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Eagan, Minnesota.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest DYNT
- Dynatronics Corporation filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update
- Dynatronics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Dynatronics Corporation
- SEC Form NT 10-Q filed by Dynatronics Corporation
- Large owner Essig Stuart acquired 16,095 shares, increasing direct ownership by 0.30% to 4,533,824 units (SEC Form 4)
- Large owner Provco Ventures 1 Lp acquired 8,043 shares, increasing direct ownership by 0.29% to 2,739,998 units (SEC Form 4)
- Director Enright Erin S. acquired 16,095 shares (SEC Form 4)
- President & CEO, CFO Baker Brian D. acquired 1,130 shares, increasing direct ownership by 0.30% to 382,675 units (SEC Form 4)
- SEC Form DEFA14A filed by Dynatronics Corporation
- SEC Form DEF 14A filed by Dynatronics Corporation